| Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy M Reig, Z Mariño, C Perelló, M Iñarrairaegui, A Ribeiro, S Lens, A Díaz, ... Journal of hepatology 65 (4), 719-726, 2016 | 1068 | 2016 |
| β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled … C Villanueva, A Albillos, J Genescà, JC Garcia-Pagan, JL Calleja, ... The lancet 393 (10181), 1597-1608, 2019 | 607 | 2019 |
| Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement A Albillos, A de la Hera, M González, JL Moya, JL Calleja, J Monserrat, ... Hepatology 37 (1), 208-217, 2003 | 584 | 2003 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 575 | 2014 |
| Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 … M Manns, D Samuel, EJ Gane, D Mutimer, G McCaughan, M Buti, ... The Lancet Infectious Diseases 16 (6), 685-697, 2016 | 524 | 2016 |
| PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy G Papatheodoridis, G Dalekos, V Sypsa, C Yurdaydin, M Buti, J Goulis, ... Journal of hepatology 64 (4), 800-806, 2016 | 499 | 2016 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 419 | 2014 |
| Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients H Hinrichsen, Y Benhamou, H Wedemeyer, M Reiser, RE Sentjens, ... Gastroenterology 127 (5), 1347-1355, 2004 | 409 | 2004 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 402 | 2020 |
| Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis JG Abraldes, C Villanueva, C Aracil, J Turnes, M Hernandez-Guerra, ... Gastroenterology 150 (5), 1160-1170. e3, 2016 | 347 | 2016 |
| Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ... The lancet Gastroenterology & hepatology 2 (5), 325-336, 2017 | 333 | 2017 |
| The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B GV Papatheodoridis, R Idilman, GN Dalekos, M Buti, H Chi, ... Hepatology 66 (5), 1444-1453, 2017 | 323 | 2017 |
| Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study A Berzigotti, A Albillos, C Villanueva, J Genescá, A Ardevol, S Augustín, ... Hepatology 65 (4), 1293-1305, 2017 | 323 | 2017 |
| Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis S Lens, E Alvarado-Tapias, Z Mariño, MC Londoño, E LLop, J Martinez, ... Gastroenterology 153 (5), 1273-1283. e1, 2017 | 279 | 2017 |
| Strategies to manage hepatitis C virus (HCV) disease burden H Wedemeyer, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, ... Journal of viral hepatitis 21, 60-89, 2014 | 279 | 2014 |
| aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis R Fan, G Papatheodoridis, J Sun, H Innes, H Toyoda, Q Xie, S Mo, ... Journal of hepatology 73 (6), 1368-1378, 2020 | 275 | 2020 |
| Portal hypertension–related complications after acute portal vein thrombosis: impact of early anticoagulation J Turnes, JC García–Pagán, M González, C Aracil, JL Calleja, C Ripoll, ... Clinical Gastroenterology and Hepatology 6 (12), 1412-1417, 2008 | 260 | 2008 |
| Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis M Simón-Talero, D Roccarina, J Martínez, K Lampichler, A Baiges, G Low, ... Gastroenterology 154 (6), 1694-1705. e4, 2018 | 234 | 2018 |
| Development of hyperdynamic circulation and response to β‐blockers in compensated cirrhosis with portal hypertension C Villanueva, A Albillos, J Genesca, JG Abraldes, JL Calleja, C Aracil, ... Hepatology 63 (1), 197-206, 2016 | 232 | 2016 |
| Propranolol Plus Placebo Versus Propranolol Plus Isosorbide–5–Mononitrate in the Prevention of A First Variceal Bleed: A Double–Blind Rct JC García-Pagán, R Morillas, R Bañares, A Albillos, C Villanueva, C Vila, ... Hepatology 37 (6), 1260-1266, 2003 | 220 | 2003 |
